The clinical trial will utilize an adaptive seamless design to evaluate the efficacy of AC-201, known as FXS5626 within the Fosun pipeline. Developed by Suzhou-based Accro Bioscience, the drug functions as a highly selective inhibitor of TYK2/JAK1. By binding to the pseudo kinase domain of these proteins, the compound aims to modulate inflammatory responses while sparing the JAK2/JAK2 signaling pathway, a mechanism researchers hope will provide a safer profile for long-term autoimmune therapy.
Fosun Pharma Industrial intends to launch the trial in mainland China as soon as operational conditions are finalized. This partnership leverages Accro’s expertise in regulatory cell death mechanisms alongside Fosun’s extensive domestic distribution and research infrastructure. The collaboration represents a strategic move to address unmet medical needs in immunology, as the companies look to transition the candidate from development toward potential commercialization.
Comments (0)
No comments yet. Be the first!